.jpg)
Pharma major Cipla is preparing to enter India's weight management space as a part of its strategy to leverage emerging healthcare opportunities and niche therapy opportunities.
In an ambitious step to transform India's healthcare system, the Adani Group announced that they are developing two AI-first Health Cities in Ahmedabad and Mumbai, with an initial investment of ?6,000 crore. The Cities will integrate healthcare...
Meril, a global leader in advanced medical solutions, successfully concluded its flagship “TechVentory” program across Delhi, Mumbai, and Kochi. The event brought together over 100 senior procurement and supply chain executives from leading...
Germany and Karnataka have decided to increase cooperation in the life sciences sector through collaborative innovation centers, co-sponsored biotech R&D award programs, and joint initiatives in green pharmaceutical manufacturing.
.jpeg)
To further enhance the global ecosystem of biosimilar, the pharma major Lupin harnessed a strategic step of having a licence and supply deal with the Zentiva Group to commercialise its biosimilar product Certolizumab Pegol in various international te
Anticipating India's leadership role in BRICS starting 2026, World Health Innovation Forum’s (WHIF) invitation to the BRICS+ Manufacturing Working Group was afforded because of Andhra Pradesh MedTech Zone’s (AMTZ) thought leadership in developing...
Eisai Pharma, a global leader in human healthcare innovation, has announced plans to establish a state-of-the-art Global Capability Centre (GCC) in Visakhapatnam, Andhra Pradesh.
.jpeg){kind=spacer}
The Medical Technology Association of India (MTaI) has strong objections to a recent notification issued by the Maharashtra Medical Council (MMC) that allows homoeopathy practitioners to administer allopathic drugs
India's pharmaceutical sector is undergoing a significant transformation, both in the discovery of new medicines and advancements in drug delivery.
VarmX, a Dutch-based biotech company headquartered in Leiden, has been given clearance by the U. S. FDA to carry out a pivotal Phase 3 clinical trial on its lead candidate, the VMX-C001. The novel bypass agent can be used to reactivate coagulati...
, CDSCO.jpg)
